Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
19.69B
Market cap19.69B
Price-Earnings ratio
13.94
Price-Earnings ratio13.94
Dividend yield
Dividend yield
Average volume
1.57M
Average volume1.57M
High today
$99.87
High today$99.87
Low today
$97.47
Low today$97.47
Open price
$98.60
Open price$98.60
Volume
851.28K
Volume851.28K
52 Week high
$112.29
52 Week high$112.29
52 Week low
$58.94
52 Week low$58.94

Stock Snapshot

The current Incyte(INCY) stock price is $98.56, with a market capitalization of 19.69B. The stock trades at a price-to-earnings (P/E) ratio of 13.94.

On 2026-05-09, Incyte(INCY) stock traded between a low of $97.47 and a high of $99.87. Shares are currently priced at $98.56, which is +1.1% above the low and -1.3% below the high.

The Incyte(INCY)'s current trading volume is 851.28K, compared to an average daily volume of 1.57M.

During the past year, Incyte(INCY) stock moved between $58.94 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $58.94 at its lowest and $112.29 at its peak.

INCY News

Simply Wall St 19h
Assessing Incyte Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy

Incyte (INCY) stock is in focus after the US FDA approved once daily Jakafi XR, along with positive Phase 3 Opzelura data in atopic dermatitis and orphan drug d...

Assessing Incyte Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy
TipRanks 20h
Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

Incyte (INCY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...

TipRanks 2d
Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

Incyte (INCY) announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura cream in adults with moderate atopic d...

Analyst ratings

52%

of 29 ratings
Buy
37.9%
Hold
51.7%
Sell
10.3%

More INCY News

Simply Wall St 2d
The Bull Case For Incyte Could Change Following FDA Approval Of Once-Daily Jakafi XR

In early May 2026, Incyte received U.S. FDA approval for Jakafi XR, a once-daily extended-release ruxolitinib tablet for multiple hematologic and graft-versus-h...

The Bull Case For Incyte Could Change Following FDA Approval Of Once-Daily Jakafi XR
Simply Wall St 3d
Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens

FDA approves Jakafi XR extended-release tablets for myelofibrosis, polycythemia vera and graft-versus-host disease. Jakafi XR offers a once-daily dosing option...

Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens
TipRanks 5d
Incyte gets orphan designation for treatment of pancreatic cancer

Incyte (INCY) Corporation was granted FDA orphan designation for a treatment of pancreatic cancer, according to a post to the agency’s website. Unlock hedge fu...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.